StockIQpro
NASDAQ:MDGL

Madrigal Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Madrigal Pharmaceuticals, Inc.'s revenue grew 432.1% in fiscal 2025 to $958.4M while operating margin rose to −31.3%. Free cash flow was −$190.0M, −19.8% of revenue, and the diluted share count rose 5.5%.Summary generated from Madrigal Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 19, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$958.4M
Revenue growth+432.1%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−31.3%
Net margin−30.1%
ROIC−31.3%
Return on equity−42.5%
Debt / equity0.56
Free cash flow−$190.0M
FCF margin−19.8%
Share count change+5.5%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue000180958
Operating income−242−294−380−498−300
Net income−242−295−374−466−288
Free cash flow−184−225−326−457−190

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations